This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nuvilex Reports Successful Establishment Of Initial Research Cell Bank To Support Late-Phase Pancreatic Cancer Clinical Trial

SILVER SPRING, Md. and VIENNA, Austria, Feb. 15, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, announced today its subsidiary, Austrianova Singapore Pte. Ltd. (ASPL) has reported the successful establishment of a research "cell bank" that will ultimately be used to obtain the numbers of cells necessary for conducting the Company's late-phase clinical trials in patients with advanced, inoperable, pancreatic cancer.

The research cell bank was established by ViruSure GmbH, an Austrian Contract Research Organization located in Vienna, Austria. The genetically augmented human cells in the cell bank are the same as those used in the two successfully completed mid-phase clinical trials in advanced non-resectable pancreatic cancer patients previously reported by Nuvilex.

ViruSure is an important international biosafety company in the biotechnology community with substantial expertise in cell culture, virus, prion, and other infectious agent testing, as well as cell growth and assessment capabilities. ViruSure assessed the purity and sterility of our cells. Before the cell bank was established, the cells were tested and shown to be free of contamination by mycoplasma, a type of bacteria that can be toxic to humans. The validation that the cells in the cell bank are "mycoplasma-free" is a prerequisite for further expansion of the cell line required for Nuvilex's late-phase clinical studies in advanced pancreatic cancer that are currently in preparation. Nuvilex is proud to announce that completion of this stage successfully showed the cells were mycoplasma-free.

Since that initial assessment, ViruSure has been carrying out the amplification of these same cells on a "fast track" basis. These cells will ultimately be used for encapsulation and subsequently implanted in patients for the treatment of advanced, inoperable pancreatic cancer.

"We are excited that the initial steps required for the commencement of additional clinical trials of our encapsulated cell therapy in advanced pancreatic cancer have been made possible through the establishment of this cell bank," said Dr. Brian Salmons, CEO of ASPL.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
YHOO $27.05 0.00%
TSLA $147.99 0.00%
AAPL $95.01 0.00%
FB $99.75 0.00%
GOOG $682.74 0.00%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs